Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(13/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(13/week)
News
United States
(421/week)
Manufacturing
(319/week)
Technology
(320/week)
Energy
(213/week)
Other Manufacturing
(264/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Factor VIII
May 31, 2020
BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
Apr 01, 2020
FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors
Mar 12, 2020
Induced Pluripotent Stem Cells Show Success in Treating Hemophilia A in Mice
Jan 02, 2020
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Dec 23, 2019
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Dec 06, 2019
Results from the PROTECT VIII Extension Study with Jivi® Published in Haemophilia
Nov 21, 2019
BioMarin Submits Marketing Authorization Application to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Jul 19, 2019
Bayer statement on voluntary recall of two lots of Kogenate® FS antihemophilic factor (recombinant) in the United States
Jun 26, 2019
Bayer to present new data from its hemophilia A portfolio at the International Society of Thrombosis and Haemostasis (ISTH) 2019 annual congress
Jun 18, 2019
Health Canada Approves Hemlibra® for Hemophilia A Patients Without Factor VIII Inhibitors
May 28, 2019
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
May 28, 2019
BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
Dec 04, 2018
Bayer Presents Five-Year Outcomes Data from the PROTECT VIII Extension Study at the 60th American Society of Hematology Annual Meeting
Aug 30, 2018
Bayer Receives FDA Approval for Jivi®, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen
Jul 09, 2018
BioMarin Partners with Believe Limited for 'Breaking Through!' Musical Theater Intensive
May 22, 2018
BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress
May 21, 2018
Sobi Emphasises Commitment to Haemophilia Community at WFH 2018 World Congress
May 17, 2018
BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress
Apr 20, 2018
Prime Therapeutics Finds Costs Double When Switching to New Extended Half-Life Hemophilia Factor Products
Apr 11, 2018
Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada
Page 1
››
Latest News
Mar 28, 2024
Slip Robotics Wins Best New Innovation in the Supply Chain at MODEX 2024
Mar 28, 2024
South Africa Motor Vehicle Industry Report 2023: Muted Domestic Sales and Export Slowdown Propose Challenges...
Mar 28, 2024
Gresham Worldwide, Inc. Announces New Head of Israeli Defense Subsidiary
Mar 28, 2024
Solace Capital Partners Provides Growth Capital to Siprocal
Mar 28, 2024
Cognyte to Announce Fourth Quarter and Full Year FY2024 Financial Results on April 9, 2024
Mar 28, 2024
Iveda Finds 84% of Americans Are Concerned About Violence in The Country; Many Believe AI Could Help
Mar 28, 2024
Voltera Welcomes Marie Robinson to Its Board of Directors
Mar 28, 2024
Former Army Maj. Gen. John B. Richardson IV Joins USAA To Lead Military Affairs
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events